Compare Ginkgo Bioworks Holdings Inc (DNA) vs McCormick & Company, Incorporated (MKC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs McCormick & Company, Incorporated — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.34 (market cap $505.73M), while McCormick & Company, Incorporated trades at $53.02 (market cap $14.22B). The key difference: McCormick & Company, Incorporated is far larger — about 28.1× Ginkgo Bioworks Holdings Inc's market cap, and McCormick & Company, Incorporated pays a 3.63% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | MKC | |
|---|---|---|
Market Cap | $505.73M | $14.22B |
Sector | Health | Consumer Staples |
52-Week High | $16.14 | $72.26 |
52-Week Low | $5.48 | $45.60 |
Enterprise Value | $607.68M | $18.82B |
Dividend Yield | — | 3.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $7.42, down 3.01% with bearish technical signals. The company reported Q2 2026 revenue of $20M, down 48% year-over-year, while maintaining a high gross margin of 68.04% but significant net losses. Analyst sentiment is mixed with 45% buy ratings amid ongoing business model transition to autonomous laboratory systems and contract research services.
The outlook remains challenging with persistent revenue declines and negative cash flow, though recent earnings beats provide some optimism. Key risks include execution of the business pivot and path to profitability. Wall Street shows cautious optimism with majority buy ratings despite fundamental headwinds.
McCormick & Company (MKC) trades at $53.10, down slightly by 0.06% today, with a bullish technical signal from moving averages but overbought RSI readings. The stock shows strong fundamentals with a P/E of 8.8, net income margin of 21.91%, and consistent earnings beats. Recent news highlights the transformative $65 billion Unilever Foods merger planned for 2027, driving positive sentiment and a consensus price target of $59.67.
MKC presents a compelling investment case with undervalued metrics and strategic growth from the Unilever deal, though risks include integration challenges and soft consumer volumes. Analysts are mixed but lean bullish, with 36.67% buy ratings. The stock offers a solid dividend and upside potential, but investors should monitor merger execution and volume trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →
